
The Physiological Responses and Adaptation of Brown Adipose Tissue to Chronic Treatment with Beta-3-Adrenergic Receptor Agonists

Phase II Trial of the Immune Checkpoint Inhibitor Nivolumab in Patients with Recurrent Select Rare CNS Cancers
National Cancer Institute (NCI) researchers are conducting a study of patients with rare central nervous system (CNS) tumors. More than 130 primary rare CNS (brain or spine) tumors have been identified. Most affect less than 2,000 people in the United States each year. This study will test whether stimulating the immune system using the drug nivolumab can shrink select rare brain or spine tumors or increase the time it takes for them to grow or spread.

Nicotinic Receptor Genetic Variation and Alcohol Reward

Brain Dopaminergic Signaling in Opioid Use Disorders

Brain Dopaminergic Signaling in Opioid use Disorders (OUD)

The Pathological Basis of MRI Signal Changes in Multiple Sclerosis: A Longitudinal In Vivo-to-Postmortem Stud

Functional Magnetic Resonance Imaging Sleep Study With Auditory Stimuli

Screening of Healthy Volunteers for Investigational Antimalarial Drugs, Malaria Vaccines, and Controlled Human Malaria Challenge
